Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., may have never had a chance to move out of the university onto pharmacy shelves without the government’s support.   Hosted on Acast. See <a style="color: grey;" href="https://acast.com/privacy" target= "_blank" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., may have never had a chance to move out of the university onto pharmacy shelves without the government’s support. Hosted on Acast. See acast.com/privacy for more information.

Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck &amp; Co. Inc., may have never had a chance to move out of the university onto pharmacy shelves without the government’s support. &nbsp; Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Merck’s new COVID-19 pill will save lives, but at what price?

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.

Share Merck’s new COVID-19 pill will save lives, but at what price?

Sign up to save your podcasts

Merck’s new COVID-19 pill will save lives, but at what price?

Merck’s new COVID-19 pill will save lives, but at what price?